Abstract
1. We have tested the hypothesis that the fall in hepatic mass with age influences the age related increase in sensitivity to warfarin. In 39 otherwise healthy outpatients, aged 50-87 years, stabilised on warfarin for prophylaxis of thromboembolism, age, mean International Normalised Ratio (INR), and mean warfarin dosage were recorded. Liver volume was measured by ultrasound, and plasma was assayed for trough concentrations of (R)- and (S)-warfarin. 2. There was a negative correlation between age and liver volume (r = -0.41; P = 0.01) and age and dose (r = -0.53; P = < 0.001) and a positive correlation between liver volume and dose (r = 0.49; P = 0.002). There was no significant correlation between dosage and (R)- and (S)-warfarin concentrations, nor between dosage and INR. 3. The regression model including both age and liver volume data showed a better fit for estimation of warfarin dosage requirement than regression models based on age and liver volume data alone. Ninety-five per cent prediction intervals for warfarin dose requirements were wide, whether age alone, or age and liver volume were used in calculations. 4. Due to inter-individual variation in warfarin dosage requirements related to other influences, both explained and unexplained, routine measurement of age and liver volume would not contribute further clinically useful information to that obtained by the INR test currently used for predicting warfarin dosage requirements.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell R. G. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle. Fed Proc. 1978 Oct;37(12):2599–2604. [PubMed] [Google Scholar]
- Breckenridge A., Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):955–961. doi: 10.1002/cpt1973146955. [DOI] [PubMed] [Google Scholar]
- Chan E., McLachlan A. J., Pegg M., MacKay A. D., Cole R. B., Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol. 1994 Jun;37(6):563–569. doi: 10.1111/j.1365-2125.1994.tb04305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eccles J. T. Control of warfarin therapy in the elderly. Age Ageing. 1975 Aug;4(3):161–165. doi: 10.1093/ageing/4.3.161. [DOI] [PubMed] [Google Scholar]
- Fennerty A., Dolben J., Thomas P., Backhouse G., Bentley D. P., Campbell I. A., Routledge P. A. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 1984 Apr 28;288(6426):1268–1270. doi: 10.1136/bmj.288.6426.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fihn S. D., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., White R. H. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993 Apr 1;118(7):511–520. doi: 10.7326/0003-4819-118-7-199304010-00005. [DOI] [PubMed] [Google Scholar]
- Gurwitz J. H., Avorn J., Ross-Degnan D., Choodnovskiy I., Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992 Jun 1;116(11):901–904. doi: 10.7326/0003-4819-116-11-901. [DOI] [PubMed] [Google Scholar]
- Hallak H. O., Wedlund P. J. Vitamin K epoxide reductase activity and its inhibition by warfarin in young and old rats. Drug Metab Dispos. 1991 Jan-Feb;19(1):278–279. [PubMed] [Google Scholar]
- Herd B., Wynne H., Wright P., James O., Woodhouse K. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol. 1991 Dec;32(6):768–770. [PMC free article] [PubMed] [Google Scholar]
- Mungall D. R., Ludden T. M., Marshall J., Hawkins D. W., Talbert R. L., Crawford M. H. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm. 1985 Jun;13(3):213–227. doi: 10.1007/BF01065653. [DOI] [PubMed] [Google Scholar]
- Naidong W., Lee J. W. Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma. J Pharm Biomed Anal. 1993 Sep;11(9):785–792. doi: 10.1016/0731-7085(93)80070-h. [DOI] [PubMed] [Google Scholar]
- Redwood M., Taylor C., Bain B. J., Matthews J. H. The association of age with dosage requirement for warfarin. Age Ageing. 1991 May;20(3):217–220. doi: 10.1093/ageing/20.3.217. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Chapman P. H., Davies D. M., Rawlins M. D. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 1979 Jun 12;15(5):319–322. doi: 10.1007/BF00558434. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Chapman P. H., Davies D. M., Rawlins M. D. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol. 1979 Sep;8(3):243–247. doi: 10.1111/j.1365-2125.1979.tb01009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shepherd A. M., Hewick D. S., Moreland T. A., Stevenson I. H. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977 Jun;4(3):315–320. doi: 10.1111/j.1365-2125.1977.tb00719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- TOOHEY M. Clinical trial of phenylindanedione as an anticoagulant. Br Med J. 1953 Mar 21;1(4811):650–652. doi: 10.1136/bmj.1.4811.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wynne H. A., Cope L. H., Mutch E., Rawlins M. D., Woodhouse K. W., James O. F. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989 Feb;9(2):297–301. doi: 10.1002/hep.1840090222. [DOI] [PubMed] [Google Scholar]
- Wynne H. A., Mutch E., James O. F., Wright P., Rawlins M. D., Woodhouse K. W. The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver. Age Ageing. 1988 Nov;17(6):401–405. doi: 10.1093/ageing/17.6.401. [DOI] [PubMed] [Google Scholar]